MX362454B - Anticuerpos capaces de unirse al factor xi de coagulacion y/o a su forma activada, factor xia, y sus usos. - Google Patents

Anticuerpos capaces de unirse al factor xi de coagulacion y/o a su forma activada, factor xia, y sus usos.

Info

Publication number
MX362454B
MX362454B MX2014013568A MX2014013568A MX362454B MX 362454 B MX362454 B MX 362454B MX 2014013568 A MX2014013568 A MX 2014013568A MX 2014013568 A MX2014013568 A MX 2014013568A MX 362454 B MX362454 B MX 362454B
Authority
MX
Mexico
Prior art keywords
binding
antibodies capable
activated form
form factor
coagulation factor
Prior art date
Application number
MX2014013568A
Other languages
English (en)
Other versions
MX2014013568A (es
Inventor
Martina Schäfer
Christoph Gerdes
Anja Buchmüller
Ricarda Finnern
Frank Dittmer
Hannah Jörissen
Andreas Wilmen
Joanna Grudzinska-Goebel
Asako Itakura
Leung Philberta Y
Erik Tucker
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MX2014013568A publication Critical patent/MX2014013568A/es
Publication of MX362454B publication Critical patent/MX362454B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos capaces de unirse con el factor Xl de coagulación y/o a su forma activada, factor Xla, y a sus procedimientos de uso, en particular procedimientos de uso como agentes que inhiben la agregación plaquetaria y, así, inhiben la formación de trombos.
MX2014013568A 2012-05-10 2013-05-08 Anticuerpos capaces de unirse al factor xi de coagulacion y/o a su forma activada, factor xia, y sus usos. MX362454B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12167438 2012-05-10
EP12181697 2012-08-24
EP13150361 2013-01-07
US201361817675P 2013-04-30 2013-04-30
PCT/EP2013/059618 WO2013167669A1 (en) 2012-05-10 2013-05-08 Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof

Publications (2)

Publication Number Publication Date
MX2014013568A MX2014013568A (es) 2014-12-08
MX362454B true MX362454B (es) 2019-01-18

Family

ID=49550177

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013568A MX362454B (es) 2012-05-10 2013-05-08 Anticuerpos capaces de unirse al factor xi de coagulacion y/o a su forma activada, factor xia, y sus usos.

Country Status (25)

Country Link
US (4) US9783614B2 (es)
EP (2) EP2847228B1 (es)
JP (2) JP6348900B2 (es)
KR (1) KR102060376B1 (es)
CN (1) CN104684932B (es)
AR (1) AR091024A1 (es)
AU (2) AU2013258043B2 (es)
BR (1) BR112014027952B1 (es)
CA (1) CA2872926C (es)
DK (1) DK2847228T3 (es)
ES (1) ES2698950T3 (es)
HK (1) HK1207091A1 (es)
HR (1) HRP20181680T1 (es)
HU (1) HUE040580T2 (es)
IL (1) IL235238B (es)
LT (1) LT2847228T (es)
MX (1) MX362454B (es)
NZ (1) NZ701121A (es)
PL (1) PL2847228T3 (es)
RS (1) RS57889B1 (es)
SG (2) SG10201609322QA (es)
SI (1) SI2847228T1 (es)
TW (2) TWI631140B (es)
WO (1) WO2013167669A1 (es)
ZA (1) ZA201407784B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2222707T3 (en) 2007-11-21 2016-04-11 Univ Oregon Health & Science Monoclonal anti-factor XI antibodies and method of use thereof
TR201904662T4 (tr) 2008-12-18 2019-05-21 Gruber Andras Anti-fxı antikorları ve kullanma yöntemleri.
PE20141825A1 (es) 2011-10-14 2014-11-29 Bristol Myers Squibb Co Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor xia
JP6033318B2 (ja) 2011-10-14 2016-11-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物
CN103987697B (zh) 2011-10-14 2017-04-26 百时美施贵宝公司 作为因子xia抑制剂的取代的四氢异喹啉化合物
WO2013167669A1 (en) * 2012-05-10 2013-11-14 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
WO2014059202A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EA032092B1 (ru) 2012-10-12 2019-04-30 Бристол-Майерс Сквибб Компани Кристаллические формы ингибитора фактора xia
WO2014160668A1 (en) 2013-03-25 2014-10-02 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
EP3988549A1 (en) 2014-01-31 2022-04-27 Bristol-Myers Squibb Company Macrocycles with heterocyclic p2' groups as factor xia inhibitors
NO2760821T3 (es) 2014-01-31 2018-03-10
PE20170287A1 (es) 2014-08-07 2017-04-05 Novartis Ag Anticuerpos anti-proteina similar a angiopoyetina 4 y metodos de uso
EP3194437B1 (en) 2014-08-07 2021-01-20 Novartis AG Angiopoietin-like 4 (angptl4) antibodies and methods of use
WO2016036893A1 (en) 2014-09-04 2016-03-10 Bristol-Myers Squibb Company Diamide macrocycles that are fxia inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
CN107405399B (zh) 2015-01-02 2022-02-08 武田药品工业株式会社 针对血浆激肽释放酶和因子xii的双特异性抗体
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
CA3025896A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
KR20180104036A (ko) 2016-01-22 2018-09-19 머크 샤프 앤드 돔 코포레이션 항-응고 인자 xi 항체
US11059905B2 (en) 2016-03-23 2021-07-13 Prothix B.V. Monoclonal antibodies against the active site of factor XI and uses thereof
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
TWI802193B (zh) 2016-06-14 2023-05-11 美商默沙東有限責任公司 抗凝血因子ｘｉ抗體
EP3515947B1 (en) * 2016-09-20 2024-05-29 Aronora, Inc. Novel antibodies against factor xi and uses thereof
US20200054719A1 (en) * 2016-11-02 2020-02-20 Erik Ian Tucker E-we thrombin analog and fibrinolytic combination
WO2018116267A2 (en) * 2016-12-23 2018-06-28 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies
IL308980A (en) * 2016-12-23 2024-01-01 Novartis Ag Antibodies against factor XI and methods of their use
RS62780B1 (sr) * 2017-01-19 2022-01-31 Bayer Pharma AG Nova stabilna formulacija za fxia antitela
CN108409863B (zh) * 2017-02-10 2023-09-26 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
US11958911B2 (en) 2017-02-10 2024-04-16 Shanghai Benemae Pharmaceutical Anti-coagulation factor XI antibody
BR112020010016A2 (pt) 2017-11-22 2020-11-10 Novartis Ag agentes de ligação de reversão para anticorpos antifator xi/xia e usos dos mesmos
JP7149721B2 (ja) 2018-03-26 2022-10-07 株式会社Pfu 情報処理装置、文字認識エンジン最適化方法及びプログラム
CA3105261A1 (en) 2018-07-05 2020-01-09 Bayer Aktiengesellschaft Method for the production of freeze-dried pellets comprising an anti-coagulation factor xia (fxia) antibody
AU2019313550B2 (en) * 2018-08-01 2024-02-08 Novo Nordisk A/S Improved procoagulant antibodies
US11546064B2 (en) 2018-08-07 2023-01-03 Nippon Telegraph And Telephone Corporation Optical transmission system and transmission mode selecting method
KR20210042352A (ko) * 2018-08-09 2021-04-19 상하이 베네마에 파머수티컬 코포레이션 항-인자 xi 항체
AU2019344801A1 (en) * 2018-09-17 2021-05-20 Board Of Regents, The University Of Texas System Compositions and methods for treating bone injury
US20210395390A1 (en) 2018-10-31 2021-12-23 Bayer Aktiengesellschaft Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies
MX2021007955A (es) * 2019-01-21 2021-10-22 Aronora Inc Nuevos anticuerpos humanizados contra el factor xi que tienen efectos anti-tromboticos y antiinflamatorios y sus usos.
US20220162338A1 (en) 2019-04-16 2022-05-26 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-fxi/fxia antibody and use thereof
CN110423278B (zh) 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
MX2022015959A (es) * 2020-07-02 2023-01-24 Beijing Tuo Jie Biopharmaceutical Co Ltd Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
DE4319041A1 (de) 1992-10-23 1994-04-28 Bayer Ag Trisubstituierte Biphenyle
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
US20030235587A1 (en) 1998-08-07 2003-12-25 Feuerstein Giora Z. Anticoagulant agents useful in treatment of thrombosis
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
BR9712523A (pt) 1996-10-14 2000-05-09 Bayer Ag Novos derivados de pirazol heterociclilmetil-substituìdos
DE19649460A1 (de) 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
WO2000007626A1 (en) 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
DE19920352A1 (de) 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
WO2003013423A2 (en) 2001-08-05 2003-02-20 Gvg, Inc. Antithrombotic agent
US7270976B2 (en) 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US20080138837A1 (en) 2004-07-19 2008-06-12 Robert Greenfield Methods and kits for detecting and measuring ADAMTS13/FXI complexes
US7279513B2 (en) 2004-11-19 2007-10-09 Nalco Company Preparation of neutralized ethylene-acrylic acid polymer dispersions and use in printing media for improvement of digital toner adhesion
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102005050497A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
DE102005050375A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
DE102005050498A1 (de) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
EP2059535B1 (en) 2006-08-18 2013-11-06 Novartis AG Prlr-specific antibody and uses thereof
CN101986783A (zh) 2007-04-23 2011-03-16 先灵公司 抗mdl-1抗体
US8574849B2 (en) 2007-10-03 2013-11-05 The University Of Vermont And State Agriculture College Methods of detection of factor XIa and tissue factor
DK2222707T3 (en) 2007-11-21 2016-04-11 Univ Oregon Health & Science Monoclonal anti-factor XI antibodies and method of use thereof
TR201820051T4 (tr) * 2008-06-19 2019-01-21 Prothix Bv Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması
US8741910B2 (en) 2008-11-25 2014-06-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
TR201904662T4 (tr) * 2008-12-18 2019-05-21 Gruber Andras Anti-fxı antikorları ve kullanma yöntemleri.
AU2010203712A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
US9365574B2 (en) 2010-05-27 2016-06-14 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US20130158028A1 (en) 2010-06-25 2013-06-20 Bayer Intellectual Property Gmbh Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
CN103097387B (zh) 2010-07-09 2016-11-02 拜耳知识产权有限责任公司 环稠合的嘧啶和三嗪以及其用于治疗和/或预防心血管疾病的用途
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
US20140171434A1 (en) 2011-01-11 2014-06-19 Bayer Pharma Aktiengessellschaft Substituted imidazopyridines and imidazopyridazines and the use thereof
US9090610B2 (en) 2011-04-21 2015-07-28 Bayer Intellectual Property Gmbh Fluoroalkyl-substituted pyrazolopyridines and use thereof
JP6096778B2 (ja) 2011-09-01 2017-03-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ピロロピラジンキナーゼ阻害剤
CA2847075A1 (en) 2011-09-02 2013-03-07 Bayer Intellectual Property Gmbh Substituted annellated pyrimidine and the use thereof
WO2013167669A1 (en) * 2012-05-10 2013-11-14 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof

Also Published As

Publication number Publication date
US20180051093A1 (en) 2018-02-22
BR112014027952A2 (pt) 2019-07-09
HRP20181680T1 (hr) 2018-12-14
RS57889B1 (sr) 2019-01-31
TWI631140B (zh) 2018-08-01
EP2847228B1 (en) 2018-07-25
IL235238B (en) 2019-08-29
TW201400504A (zh) 2014-01-01
AU2018200850C1 (en) 2020-03-12
CA2872926C (en) 2022-07-05
KR20150008166A (ko) 2015-01-21
EP3404045A1 (en) 2018-11-21
KR102060376B1 (ko) 2019-12-30
PL2847228T3 (pl) 2019-03-29
CN104684932B (zh) 2019-03-12
AU2013258043A1 (en) 2014-11-13
DK2847228T3 (en) 2018-11-19
US9783614B2 (en) 2017-10-10
HK1207091A1 (en) 2016-01-22
SG11201406719UA (en) 2014-11-27
CN104684932A (zh) 2015-06-03
LT2847228T (lt) 2018-11-12
AU2013258043B2 (en) 2017-11-30
TWI644925B (zh) 2018-12-21
EP2847228A1 (en) 2015-03-18
AR091024A1 (es) 2014-12-30
US10221247B2 (en) 2019-03-05
JP2015517305A (ja) 2015-06-22
US20180112009A1 (en) 2018-04-26
ZA201407784B (en) 2019-01-30
CA2872926A1 (en) 2013-11-14
US10040866B2 (en) 2018-08-07
US20190284300A1 (en) 2019-09-19
WO2013167669A1 (en) 2013-11-14
SI2847228T1 (sl) 2018-11-30
BR112014027952B1 (pt) 2022-06-21
NZ701121A (en) 2017-06-30
IL235238A0 (en) 2014-12-31
HUE040580T2 (hu) 2019-03-28
US20150099298A1 (en) 2015-04-09
JP6348900B2 (ja) 2018-06-27
TW201811834A (zh) 2018-04-01
SG10201609322QA (en) 2017-01-27
MX2014013568A (es) 2014-12-08
ES2698950T3 (es) 2019-02-06
AU2018200850A1 (en) 2018-02-22
JP2018148920A (ja) 2018-09-27
US11046783B2 (en) 2021-06-29
AU2018200850B2 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
NZ701121A (en) Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
WO2017015622A8 (en) Gdf11 binding proteins and uses thereof
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
MX362582B (es) Compuestos triciclicos fusionados de urea como inhibidores de raf quinasa y/o dimero de raf quinasa.
WO2012140274A3 (en) Agonists and antagonists of the wnt pathway
MX2017016345A (es) Proteinas de fusion para inhibir la angiogenesis.
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
TN2012000366A1 (en) Anticoagulant antidotes
MX2016014862A (es) Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2.
WO2014086982A3 (en) Stable metal compounds, their compositions and methods of their use
MY179243A (en) Supplemented fish feed
WO2012050611A3 (en) Aptamers to glycoprotein vi
MX345926B (es) Nuevas composiciones, producción de las mismas y uso de las mismas para la producción de poliamidas coladas.
EA033460B1 (ru) Замещенные [1,2,4]триазольные соединения в качестве фунгицидов
TN2013000388A1 (en) Anticoagulant antidotes
WO2013190274A3 (en) Biodegradable compositions
MX2016014416A (es) Anticuerpos anti-her3 que se unen a la horquilla beta de her3.
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
MX354501B (es) Ingrediente perfumante de la familia galbano.
PH12016501608A1 (en) Peptides and methods of use
CY1120786T1 (el) Αντισωματα ικανα να δεσμευονται στον παραγοντα πηξης xi και/ή στην ενεργοποιημενη μορφη αυτου, τον παραγοντα χια, και χρησεις αυτων

Legal Events

Date Code Title Description
FG Grant or registration